Colin Young

Colin Young is a Variant Assessment Scientist II at Ambry Genetics, specializing in clinical variant curation for hereditary cancer predisposition, with expertise in genes such as BRCA1, BRCA2, and CHEK2. Prior experience includes serving as a Variant Assessment Scientist I at Huntsman Cancer Institute, where genomic engineering techniques like CRISPR/Cas9 were applied to identify pathogenic cancer gene mutations. Colin's research background also includes a role as a Graduate Research Assistant at the University of Utah, focusing on developing cost-effective disease diagnostics, and leading outreach initiatives as a National Science Foundation Outreach Team Leader. Colin holds a PhD in Chemical Engineering and a Bachelor of Science in Chemical Engineering, both from the University of Utah.